CD14 release induced by P2X7 receptor restricts inflammation and increases survival during sepsis.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
02 11 2020
Historique:
received: 08 07 2020
accepted: 31 10 2020
pubmed: 3 11 2020
medline: 17 3 2021
entrez: 2 11 2020
Statut: epublish

Résumé

P2X7 receptor activation induces the release of different cellular proteins, such as CD14, a glycosylphosphatidylinositol (GPI)-anchored protein to the plasma membrane important for LPS signaling via TLR4. Circulating CD14 has been found at elevated levels in sepsis, but the exact mechanism of CD14 release in sepsis has not been established. Here, we show for first time that P2X7 receptor induces the release of CD14 in extracellular vesicles, resulting in a net reduction in macrophage plasma membrane CD14 that functionally affects LPS, but not monophosphoryl lipid A, pro-inflammatory cytokine production. Also, we found that during a murine model of sepsis, P2X7 receptor activity is important for maintaining elevated levels of CD14 in biological fluids and a decrease in its activity results in higher bacterial load and exacerbated organ damage, ultimately leading to premature deaths. Our data reveal that P2X7 is a key receptor for helping to clear sepsis because it maintains elevated concentrations of circulating CD14 during infection. When the immune system detects an infection, it often launches an inflammatory response to fight off the disease. This defense mechanism is activated by a cascade of signaling molecules that can aggravate inflammation, causing it to damage the body’s own tissues and organs. This life-threatening reaction is referred to as sepsis, and kills around 11 million people each year. New approaches are therefore needed to help alleviate the damage caused by this condition. The inflammatory response is often triggered by proteins called receptors, which sit on the surface of immune cells. When these receptors are activated, they induce cells to secrete proteins that travel around the body and activate immune cells that can eliminate the infection. In 2016, a group of researchers showed that a receptor called P2X7 stimulates the release of a signaling molecule called CD14. Patients with sepsis often have elevated amounts of CD14 in their bloodstream. Yet, it remained unclear what causes this rise in CD14 and what role this molecule plays in the development of sepsis. Now, Alarcón-Vila et al. – including some of the researchers involved in the 2016 study – have investigated the role of P2X7 in mice undergoing sepsis. This was done by puncturing the mice’s intestines, causing bacteria to leak out and initiate an over-active immune response. Alarcón-Vila et al. found that mice lacking the P2X7 receptor had less CD14 and struggled to eliminate the bacterial infection from their system. This increase in bacteria caused excessive damage to the mice’s organs, ultimately leading to premature death. These findings suggest that P2X7 plays an important role in preventing the onset of sepsis by helping maintain high levels of CD14 following infection. This result could help to identify new therapies that reduce the mortality rates of septic infections.

Autres résumés

Type: plain-language-summary (eng)
When the immune system detects an infection, it often launches an inflammatory response to fight off the disease. This defense mechanism is activated by a cascade of signaling molecules that can aggravate inflammation, causing it to damage the body’s own tissues and organs. This life-threatening reaction is referred to as sepsis, and kills around 11 million people each year. New approaches are therefore needed to help alleviate the damage caused by this condition. The inflammatory response is often triggered by proteins called receptors, which sit on the surface of immune cells. When these receptors are activated, they induce cells to secrete proteins that travel around the body and activate immune cells that can eliminate the infection. In 2016, a group of researchers showed that a receptor called P2X7 stimulates the release of a signaling molecule called CD14. Patients with sepsis often have elevated amounts of CD14 in their bloodstream. Yet, it remained unclear what causes this rise in CD14 and what role this molecule plays in the development of sepsis. Now, Alarcón-Vila et al. – including some of the researchers involved in the 2016 study – have investigated the role of P2X7 in mice undergoing sepsis. This was done by puncturing the mice’s intestines, causing bacteria to leak out and initiate an over-active immune response. Alarcón-Vila et al. found that mice lacking the P2X7 receptor had less CD14 and struggled to eliminate the bacterial infection from their system. This increase in bacteria caused excessive damage to the mice’s organs, ultimately leading to premature death. These findings suggest that P2X7 plays an important role in preventing the onset of sepsis by helping maintain high levels of CD14 following infection. This result could help to identify new therapies that reduce the mortality rates of septic infections.

Identifiants

pubmed: 33135636
doi: 10.7554/eLife.60849
pii: 60849
pmc: PMC7690950
doi:
pii:

Substances chimiques

Lipopolysaccharide Receptors 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
Nlrp3 protein, mouse 0
P2rx7 protein, mouse 0
Receptors, Purinergic P2X7 0
Casp4 protein, mouse EC 3.4.22.-
Caspases, Initiator EC 3.4.22.-
Casp1 protein, mouse EC 3.4.22.36
Caspase 1 EC 3.4.22.36

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fundacion Seneca
ID : 21081/PDC/19
Pays : International
Organisme : Ministerio de Economía y Competitividad
ID : SAF2017-88276-R
Pays : International
Organisme : European Research Council
ID : 614578
Pays : International
Organisme : Fundación Séneca
ID : 21081/PDC/19
Pays : International
Organisme : Fundación Séneca
ID : 20859/PI/18
Pays : International
Organisme : European Research Council
ID : 899636
Pays : International
Organisme : Fundacion Seneca
ID : 20859/PI/18
Pays : International

Informations de copyright

© 2020, Alarcón-Vila et al.

Déclaration de conflit d'intérêts

CA, AB, Cd, CM, JM, HM, CG, PP No competing interests declared

Références

Nat Commun. 2019 Jun 20;10(1):2711
pubmed: 31221993
Nat Rev Immunol. 2020 Mar;20(3):143-157
pubmed: 31690840
Hum Immunol. 2007 Sep;68(9):730-8
pubmed: 17869646
Medicine (Baltimore). 2015 Nov;94(47):e2158
pubmed: 26632748
Crit Care. 2014 Sep 05;18(5):507
pubmed: 25190134
Nat Immunol. 2005 Jun;6(6):565-70
pubmed: 15895089
J Control Release. 2018 Oct 10;287:67-77
pubmed: 30110615
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Cytokine Growth Factor Rev. 2019 Aug;48:24-31
pubmed: 31296363
Immunology. 2012 May;136(1):64-77
pubmed: 22260507
J Immunol. 1995 Jun 15;154(12):6529-32
pubmed: 7539025
Immunol Cell Biol. 2005 Oct;83(5):462-7
pubmed: 16174094
J Immunol. 2004 Apr 1;172(7):4470-9
pubmed: 15034063
Nat Protoc. 2009;4(1):31-6
pubmed: 19131954
Immunity. 2001 Nov;15(5):825-35
pubmed: 11728343
Am J Respir Crit Care Med. 2006 Jan 1;173(1):122-9
pubmed: 16210672
Cell Death Dis. 2019 Nov 25;10(12):882
pubmed: 31767863
J Exp Med. 2010 Nov 22;207(12):2689-701
pubmed: 21078886
Front Cell Infect Microbiol. 2013 Feb 12;3:3
pubmed: 23408095
J Leukoc Biol. 1997 Dec;62(6):786-94
pubmed: 9400820
FASEB J. 2017 May;31(5):1891-1902
pubmed: 28122919
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
FASEB J. 2015 Sep;29(9):3626-37
pubmed: 26060214
PLoS One. 2008 Jul 09;3(7):e2599
pubmed: 18612415
Immunity. 2017 Jan 17;46(1):38-50
pubmed: 27986454
Curr Opin Immunol. 2008 Aug;20(4):420-5
pubmed: 18625310
J Biol Chem. 2001 Jan 5;276(1):125-32
pubmed: 11016935
J Immunol. 2005 Nov 1;175(9):6042-9
pubmed: 16237099
FASEB J. 2012 Jul;26(7):2951-62
pubmed: 22490780
Sci Rep. 2016 Mar 03;6:22586
pubmed: 26935289
Neuroscience. 2007 Jun 8;146(4):1817-28
pubmed: 17478048
N Engl J Med. 2012 Dec 13;367(24):2322-33
pubmed: 23234515
J Immunol. 2009 Apr 15;182(8):5052-62
pubmed: 19342685
Infect Immun. 2018 Mar 22;86(4):
pubmed: 29311239
Science. 1995 Mar 31;267(5206):2000-3
pubmed: 7535475
J Immunol. 2007 Aug 1;179(3):1913-25
pubmed: 17641058
Immunity. 2017 Jul 18;47(1):15-31
pubmed: 28723547
J Endotoxin Res. 2005;11(4):225-9
pubmed: 16176659
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
J Immunol. 1996 Nov 1;157(9):4119-25
pubmed: 8892647
Blood. 1998 Nov 15;92(10):3521-8
pubmed: 9808543
Front Cell Infect Microbiol. 2013 Jul 24;3:32
pubmed: 23898465
Front Immunol. 2017 May 23;8:579
pubmed: 28588578
J Leukoc Biol. 2017 Jan;101(1):193-204
pubmed: 27581539
Biochim Biophys Acta. 1989 Jul 7;1008(2):213-22
pubmed: 2472171

Auteurs

Cristina Alarcón-Vila (C)

Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Alberto Baroja-Mazo (A)

Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Carlos de Torre-Minguela (C)

Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Carlos M Martínez (CM)

Plataforma de Patología, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Murcia, Spain.

Juan J Martínez-García (JJ)

Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Helios Martínez-Banaclocha (H)

Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Carlos García-Palenciano (C)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Pablo Pelegrin (P)

Línea de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH